David H. Miller

发表

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

David H. Miller, Jeffrey A. Cohen, S. Reingold, 2017, The Lancet Neurology.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Ludwig Kappos, Xavier Montalban, David H. Miller, 2016, The Lancet.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

David H. Miller, D. MacManus, C. Wheeler-Kingshott, 2015, Neurology.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

David H. Miller, D. Arnold, A. Bar-Or, 2014, Annals of clinical and translational neurology.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

David H. Miller, M. Hutchinson, E. Havrdová, 2012, The New England journal of medicine.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Ludwig Kappos, Gavin Giovannoni, Frances Lynn, 2006, The New England journal of medicine.

Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis

O. Ciccarelli, D. Altmann, K. Miszkiel, 2016, Multiple sclerosis.

Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value

David H. Miller, O. Ciccarelli, H. Kearney, 2015, Nature Reviews Neurology.

Cervical cord lesion load is associated with disability independently from atrophy in MS

David H. Miller, O. Ciccarelli, C. Wheeler-Kingshott, 2015, Neurology.

Vision and vision-related outcome measures in multiple sclerosis

David H. Miller, Jeffrey A. Cohen, S. Reingold, 2014, Brain : a journal of neurology.

Diagnosis of multiple sclerosis: progress and challenges

David H. Miller, Franz Fazekas, F. Fazekas, 2017, The Lancet.

Primary-progressive multiple sclerosis

David H. Miller, S. Leary, David H Miller, 2007, The Lancet Neurology.

A controlled trial of natalizumab for relapsing multiple sclerosis.

David H. Miller, K. Miszkiel, L. Blumhardt, 2003, The New England journal of medicine.

Diffusion tensor imaging of post mortem multiple sclerosis brain

Gareth J. Barker, David H. Miller, Paul S. Tofts, 2007, NeuroImage.

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

David H. Miller, G. Barker, K. Schmierer, 2004, Annals of neurology.

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

David H. Miller, D. Altmann, Kenneth J. Smith, 2010, The Lancet Neurology.

Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes

David H. Miller, C. Wheeler-Kingshott, D. Chard, 2010, Journal of magnetic resonance imaging : JMRI.

Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.

Xavier Golay, David H. Miller, Frank Riemer, 2013, Brain : a journal of neurology.

Improved MRI quantification of spinal cord atrophy in multiple sclerosis

David H. Miller, O. Ciccarelli, C. Wheeler-Kingshott, 2011, Journal of magnetic resonance imaging : JMRI.

Association between pathological and MRI findings in multiple sclerosis

Massimo Filippi, Frederik Barkhof, Bradley J Erickson, 2012, The Lancet Neurology.

Pregnancy, sex and hormonal factors in multiple sclerosis

David H. Miller, S. Reingold, X. Montalban, 2014, Multiple sclerosis.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2014, JAMA neurology.

Gray matter atrophy is related to long‐term disability in multiple sclerosis

David H. Miller, A. Thompson, V. Anderson, 2008, Annals of neurology.

Optic neuritis

David H. Miller, A. Toosy, D. Mason, 2014, The Lancet Neurology.

The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases

David H. Miller, Jeremy Chataway, Michael H Barnett, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Imaging outcomes for trials of remyelination in multiple sclerosis

David H. Miller, Claudia A M Wheeler-Kingshott, C. Wheeler-Kingshott, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI

V. Anderson, C. Wheeler-Kingshott, K. Schmierer, 2013, Multiple sclerosis.

Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study

Christian M Kerskens, Frauke Zipp, Arno Villringer, 2004, Multiple sclerosis.

A Magnetization Transfer Analysis of the Thalamus in Schizophrenia

Gareth J. Barker, David H. Miller, Maria A. Ron, 2002 .

Diffusion tensor imaging in early relapsing-remitting multiple sclerosis

Olga Ciccarelli, Alan J Thompson, Gareth J Barker, 2001, Multiple sclerosis.

1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis

Geoff J. M. Parker, Gareth J. Barker, David H. Miller, 1999, Journal of Neurology.

Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis

A. Thompson, V. Stevenson, S. Leary, 1999, Journal of Neurology.

A multicenter measurement of magnetization transfer ratio in normal white matter

David H. Miller, G. Barker, F. Barkhof, 1999, Journal of magnetic resonance imaging : JMRI.

Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance

David H. Miller, M. Horsfield, G. Barker, 1996, Magnetic resonance in medicine.

Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain

David H. Miller, G. Barker, P. Tofts, 2007, Journal of magnetic resonance imaging : JMRI.

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

David H. Miller, Alan J Thompson, Gordon T Plant, 2004, Brain : a journal of neurology.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS

David H. Miller, F. Barkhof, X. Montalban, 2014, Annals of clinical and translational neurology.

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2007, The Lancet.

Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI

Xavier Golay, David H. Miller, Varun Sethi, 2012, Journal of Neurology, Neurosurgery & Psychiatry.

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

David H. Miller, A. Thompson, F. Barkhof, 2002, Brain : a journal of neurology.

Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis.

David H. Miller, O. Ciccarelli, A. Thompson, 2015, Brain : a journal of neurology.

MS Cortical Lesions on DIR: Not Quite What They Seem?

M. Ron, X. Golay, C. Wheeler-Kingshott, 2013, PloS one.

White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis

David H. Miller, O. Ciccarelli, A. Thompson, 2016, Multiple sclerosis.

An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis

David H. Miller, S. Ourselin, W. Brownlee, 2017, Brain : a journal of neurology.

Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis

David H. Miller, S. Ourselin, C. Sudre, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis.

David H. Miller, C. Wheeler-Kingshott, N. Muhlert, 2015, Brain : a journal of neurology.

MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study

Marco Rovaris, Massimo Filippi, Xavier Montalban, 2007, The Lancet Neurology.

Adaptive cortical plasticity in higher visual areas after acute optic neuritis

Stephen J. Jones, David H. Miller, Alan J Thompson, 2005, Annals of neurology.

Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study

G J Barker, E T Bullmore, David H. Miller, 2000, Journal of neurology, neurosurgery, and psychiatry.

High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.

David H. Miller, Roger J Ordidge, Sebastian Brandner, 2010, Brain : a journal of neurology.

A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis

David H. Miller, M. Ron, C. Wheeler-Kingshott, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Diffusion imaging of the spinal cord in vivo: Estimation of the principal diffusivities and application to multiple sclerosis

David H. Miller, C A Clark, D. Miller, 2000, Magnetic resonance in medicine.

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

David H. Miller, A. Thompson, D. Altmann, 2012, The Lancet Neurology.

A novel approach with “skeletonised MTR” measures tract‐specific microstructural changes in early primary‐progressive MS

David H. Miller, O. Ciccarelli, A. Thompson, 2014, Human brain mapping.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop

David H. Miller, X. Montalban, T. Derfuss, 2018, Multiple sclerosis.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study

D. MacManus, M. Sormani, X. Montalban, 2018, Annals of clinical and translational neurology.

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

David H. Miller, S. Reingold, F. Barkhof, 2009, Nature Reviews Neurology.

Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the multiple sclerosis spinal cord.

David H. Miller, O. Ciccarelli, C. Wheeler-Kingshott, 2014, Brain : a journal of neurology.

Grey and White Matter Magnetisation Transfer Ratio Measurements in the Lumbosacral Enlargement: A Pilot In Vivo Study at 3T

C. Wheeler-Kingshott, R. Samson, M. Yiannakas, 2015, PloS one.

Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke

David H. Miller, A. Thompson, G. Barker, 2000, Journal of neurology, neurosurgery, and psychiatry.

Corpus callosum damage predicts disability progression and cognitive dysfunction in primary‐progressive MS after five years

Mara Cercignani, David H. Miller, Olga Ciccarelli, 2013, Human brain mapping.

Diffusion MRI‐based cortical complexity alterations associated with executive function in multiple sclerosis

David H. Miller, M. Ron, G. Parker, 2013, Journal of magnetic resonance imaging : JMRI.

An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography.

David H. Miller, G. Plant, D. Altmann, 2007, Brain : a journal of neurology.

Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis

Stephen J. Jones, David H. Miller, A. Thompson, 2005, Annals of neurology.

Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis

Massimo Filippi, Frederik Barkhof, David H. Miller, 2003, Journal of magnetic resonance imaging : JMRI.

Clinically isolated syndromes

David H. Miller, Olga Ciccarelli, O. Ciccarelli, 2012, The Lancet Neurology.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

David H. Miller, F. Barkhof, X. Montalban, 2009, The Lancet Neurology.

Lack of association between antimyelin antibodies and progression to multiple sclerosis.

David H. Miller, F. Barkhof, X. Montalban, 2007, The New England journal of medicine.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

David H. Miller, A. Thompson, M. Sormani, 2018, Multiple sclerosis.

Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis

O. Ciccarelli, F. Barkhof, K. Miszkiel, 2018, Neurology.

Should the symptomatic region be included in dissemination in space in MRI criteria for MS?

O. Ciccarelli, K. Miszkiel, W. Brownlee, 2016, Neurology.

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT

David H. Miller, F. Barkhof, X. Montalban, 2015, Neurology.

Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM

Mara Cercignani, David H. Miller, Olga Ciccarelli, 2009, Human brain mapping.

Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability

A. J. Thompson, D. H. Miller, M. Cercignani, 2007, NeuroImage.

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

D. MacManus, X. Montalban, T. Yousry, 2012, The Lancet Neurology.

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

David H. Miller, G. Barker, D. MacManus, 2004, Journal of Neurology.

Reproducibility of fMRI in the clinical setting: Implications for trial designs

Massimo Filippi, Ludwig Kappos, Xavier Montalban, 2008, NeuroImage.

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ivan Rektor, David H. Miller, 2008, The Lancet.

Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging

David H. Miller, O. Ciccarelli, F. Barkhof, 2014, The Lancet Neurology.

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

David H. Miller, D. MacManus, L. Kappos, 2012, Multiple sclerosis.

Fatigue is not associated with raised inflammatory markers in multiple sclerosis

David H. Miller, A. Thompson, G. Giovannoni, 2001, Neurology.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

L. Kappos, C. Polman, P. Calabresi, 2009, Journal of Neurology.

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions

David H. Miller, O. Ciccarelli, A. Thompson, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.

David H. Miller, O. Ciccarelli, A. Thompson, 2002, The New England journal of medicine.

Periventricular lesions and MS diagnostic criteria in young adults with typical clinically isolated syndromes

O. Ciccarelli, D. Altmann, K. Miszkiel, 2017, Multiple sclerosis.

Motor network efficiency and disability in multiple sclerosis

Matteo Pardini, Rebecca S. Samson, David H. Miller, 2015, Neurology.

Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria

O. Ciccarelli, D. Altmann, W. Brownlee, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging

Gareth J. Barker, Alan J. Thompson, David H. Miller, 2003, Journal of Neurology.

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

David H. Miller, F. Barkhof, M. Rovaris, 2012, Nature Reviews Neurology.

From diffusion tractography to quantitative white matter tract measures: a reproducibility study

Gareth J. Barker, Alan J. Thompson, David H. Miller, 2003, NeuroImage.

Energy failure in multiple sclerosis and its investigation using MR techniques

David H. Miller, X. Golay, C. Wheeler-Kingshott, 2011, Journal of Neurology.

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?

David H. Miller, O. Ciccarelli, A. Thompson, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Infections and MS

David H. Miller, A. Goodman, David H. Miller, 2002, Neurology.

Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study.

Stephen J. Jones, Alan J Thompson, Gordon T Plant, 2004, Journal of neurology.

Neuroplasticity predicts outcome of optic neuritis independent of tissue damage

David H. Miller, O. Ciccarelli, A. Thompson, 2010, Annals of neurology.

MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation”

David H. Miller, F. Barkhof, M. Rovaris, 2006, The Lancet Neurology.

Gray matter atrophy rate as a marker of disease progression in AD

Nick C. Fox, Kelvin K. Leung, Nick C Fox, 2012, Neurobiology of Aging.

Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis.

David H. Miller, A. Thompson, G. Plant, 2006, Brain : a journal of neurology.

Characterizing function–structure relationships in the human visual system with functional MRI and diffusion tensor imaging

Geoff J. M. Parker, Alan J. Thompson, David H. Miller, 2004, NeuroImage.

Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters

G J Barker, A J Thompson, J W Thorpe, 1996, Journal of magnetic resonance imaging : JMRI.

The persistent vegetative state

R. Howard, David H Miller, David H. Miller, 1995, BMJ.

Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial

David H. Miller, A. Toosy, K. Schmierer, 2016, The Lancet Neurology.

Auditory Efferent Function Is Affected in Multiple Sclerosis

L. Luxon, D. Prasher, B. Ćeranić, 2007, Ear and hearing.

New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes

A. Thompson, G. Plant, D. MacManus, 2003, Annals of neurology.

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

David H. Miller, Alan J Thompson, Gordon T Plant, 2002, Annals of neurology.

A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials.

Stephen J. Jones, David H. Miller, G. Plant, 2010, Brain : a journal of neurology.

Scanning Laser Polarimetry Quantification of Retinal Nerve Fiber Layer Thinning Following Optic Neuritis

Stephen J. Jones, A. Thompson, G. Plant, 2010, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually‐edited SIENA and SIENAX

Marco Rovaris, Massimo Filippi, Christian Enzinger, 2007, Journal of magnetic resonance imaging : JMRI.

Functional Connectivity Alterations Reveal Complex Mechanisms Based on Clinical and Radiological Status in Mild Relapsing Remitting Multiple Sclerosis

David H. Miller, E. D’Angelo, L. Debernard, 2018, Front. Neurol..

Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy

S. Anand Trip, Patricio G. Schlottmann, Stephen J. Jones, 2006, NeuroImage.

Optic radiation changes after optic neuritis detected by tractography‐based group mapping

Geoff J M Parker, David H. Miller, Olga Ciccarelli, 2005, Human brain mapping.

White and gray matter damage in primary progressive MS

David H. Miller, O. Ciccarelli, A. Thompson, 2016, Neurology.

Upper cervical cord area in early relapsing‐remitting multiple sclerosis: Cross‐sectional study of factors influencing cord size

David H. Miller, A. Thompson, D. Altmann, 2006, Journal of magnetic resonance imaging : JMRI.

What lies beneath grey matter atrophy in multiple sclerosis?

David H. Miller, D. Chard, David H. Miller, 2016, Brain : a journal of neurology.

Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis.

C. Wheeler-Kingshott, N. Muhlert, H. Kearney, 2015, Multiple sclerosis and related disorders.

Localization of grey matter atrophy in early RRMS

Alan J. Thompson, Bertrand Audoin, David H. Miller, 2006, Journal of Neurology.

Fully automated grey and white matter spinal cord segmentation

David H. Miller, S. Ourselin, O. Ciccarelli, 2016, Scientific Reports.

Magnetic resonance in monitoring the treatment of multiple sclerosis

D. Miller, D H Miller, David H. Miller, 1994, Annals of neurology.

Investigating Cervical Spinal Cord Structure Using Axial Diffusion Tensor Imaging

Gareth J. Barker, David H. Miller, David H. Miller, 2002, NeuroImage.

Early factors associated with axonal loss after optic neuritis

Stephen J. Jones, G. Plant, D. Altmann, 2011, Annals of neurology.

Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study.

Mara Cercignani, Jorge Sepulcre, David H. Miller, 2006, Archives of neurology.

TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis

Alan J Thompson, Waqar Rashid, A. Thompson, 2010, Multiple sclerosis.

Predicting Clinically Definite Multiple Sclerosis from Onset Using SVM

David H. Miller, Daniel C. Alexander, David H. Miller, 2011, MLINI.

Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis

David H. Miller, F. Barkhof, M. Rocca, 2013, Journal of Neurology.

Cerebral Arterial Bolus Arrival Time is Prolonged in Multiple Sclerosis and Associated with Disability

David H. Miller, X. Golay, C. Wheeler-Kingshott, 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation

David H. Miller, P. Boulby, G. Barker, 2008, Magnetic resonance in medicine.

A serial MRI study following optic nerve mean area in acute optic neuritis.

Stephen J. Jones, David H. Miller, Alan J Thompson, 2004, Brain : a journal of neurology.

Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis.

Stephen J. Jones, David H. Miller, Gordon T Plant, 2004, AJNR. American journal of neuroradiology.

Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: A voxel-based analysis study

David H. Miller, Varun Sethi, Nils Muhlert, 2015, Multiple sclerosis.

Baló's concentric sclerosis

David H. Miller, T. Hardy, David H. Miller, 2014 .

Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR

Alan J. Thompson, David H. Miller, Olga Ciccarelli, 2002, Journal of Neurology.

Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study.

David H. Miller, O. Ciccarelli, T. Schneider, 2017, Functional neurology.

Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis

Olga Ciccarelli, Alan J Thompson, Nikos Gorgoraptis, 2010, Multiple sclerosis.

Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging.

David H. Miller, M. Rovaris, M. Filippi, 2012, Radiology.

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

David H. Miller, A. Thompson, C. Wheeler-Kingshott, 2011, Trials.

Assessing Neuronal Metabolism In Vivo by Modeling Imaging Measures

David H. Miller, O. Ciccarelli, N. De Stefano, 2010, The Journal of Neuroscience.

Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups

David H. Miller, A. Thompson, M. Rovaris, 1996, Journal of Neurology.

Erratum to: Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis

F. Barkhof, M. Filippi, M. Rocca, 2014, Journal of Neurology.

The Increasing Prevalence of Multiple Sclerosis in New Zealand

David H. Miller, S. Alla, L. Debernard, 2014, Neuroepidemiology.

Investigation of white matter pathology in ALS and PLS using tract‐based spatial statistics

Timothy Edward John Behrens, Heidi Johansen-Berg, Paul M. Matthews, 2009, Human brain mapping.

Clinically isolated syndromes and the relationship to multiple sclerosis

W. Brownlee, David H. Miller, 2014, Journal of Clinical Neuroscience.

What you see depends on how you look

David H. Miller, Declan T. Chard, D. Chard, 2009, Neurology.

Assessment and correction of B1‐induced errors in magnetization transfer ratio measurements

Massimo Filippi, Frederik Barkhof, Stefan Ropele, 2005, Magnetic resonance in medicine.

Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease

David H. Miller, Mustafa M. Almuqbel, T. Anderson, 2019, Front. Neurol..

Disease-modifying treatments in multiple sclerosis

David H. Miller, A. Compston, J. Noseworthy, 2006 .

Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis

David H. Miller, David H. Miller, 2004, NeuroRX.

Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis

Tracy R. Melzer, Sridhar Alla, David H. Miller, 2015, Psychiatry Research: Neuroimaging.

Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome

David H. Miller, G. Barker, C. Davie, 1997, Movement disorders : official journal of the Movement Disorder Society.

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis

David H. Miller, T. Friede, S. Todd, 2011, Multiple sclerosis.

HLA-DRB1*15 influences the development of brain tissue damage in early PPMS

David H. Miller, O. Ciccarelli, A. Thompson, 2014, Neurology.

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

David H. Miller, F. Barkhof, X. Montalban, 2012, Multiple sclerosis.

Effects of interferon beta-1 b on cognitive performance in patients with a first event suggestive of multiple

F. Barkhof, X. Montalban, L. Kappos, 2012 .

Network Efficiency As A Final Common Pathway For Cognitive Deficits In Multiple Sclerosis: A Single Network Graph Theory Study (P6.128)

M. Ron, C. Wheeler-Kingshott, D. Altmann, 2014 .

Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registration‐Based Methods

Chris Frost, Nick C Fox, Waqar Rashid, 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Magnetic resonance imaging measures of brain atrophy in multiple sclerosis

Nick C Fox, David H. Miller, V. Anderson, 2006, Journal of magnetic resonance imaging : JMRI.

Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study.

Mara Cercignani, Lluís Ramió-Torrentà, David H. Miller, 2005, Brain : a journal of neurology.

The Use of the Lumbosacral Enlargement as an Intrinsic Imaging Biomarker: Feasibility of Grey Matter and White Matter Cross-Sectional Area Measurements Using MRI at 3T

David H. Miller, C. Wheeler-Kingshott, M. Yiannakas, 2014, PloS one.

Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis.

David H. Miller, P. Calabresi, S. Hickman, 2008, Archives of neurology.

Natalizumab Therapy for Multiple Sclerosis

J. Chataway, David H. Miller, 2013, Neurotherapeutics.

A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis

David H. Miller, C. Polman, D. Altmann, 2007, Journal of Neurology.

Brain atrophy, interferon beta, and treatment trials in multiple sclerosis

David H. Miller, David H Miller, David H. Miller, 2004, The Lancet.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

David H. Miller, Deborah M. Miller, L. Kappos, 2007, Annals of neurology.

Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups

Varun Sethi, Nils Muhlert, M. Ron, 2014, Multiple sclerosis.

Image registration and subtraction to detect active T2 lesions in MS: an interobserver study

Massimo Filippi, Frederik Barkhof, Franz Fazekas, 2002, Journal of Neurology.

Disability and T2 MRI lesions: a 20 year follow-up of patients with relapse onset of MS

A. Thompson, D. Altmann, K. Miszkiel, 2008 .

Reduced R2′ in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content

Xavier Golay, David Paling, X. Golay, 2012, Journal of Neurology, Neurosurgery & Psychiatry.

Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging

Andreas Hadjiprocopis, David H. Miller, Alan Thompson, 2008, Journal of Neurology.

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis

David H. Miller, K. Miszkiel, G. Rice, 2005, Multiple sclerosis.

MRI monitoring of MS in clinical trials

David H. Miller, 2002, Clinical Neurology and Neurosurgery.

Magnetic Resonance Imaging of Patients with Isolated Idiopathic Optic Neuritis, Brainstem Syndromes and Myelopathy

David H. Miller, David H. Miller, 1996 .

The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology

Alan J Thompson, Geoffrey J M Parker, A. Thompson, 2002, Journal of magnetic resonance imaging : JMRI.

Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis

Alan J. Thompson, David H. Miller, Lluís Ramió-Torrentà, 2004, NeuroImage.

The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial

L. Kappos, C. Polman, F. Lublin, 2005 .

Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis.

Mara Cercignani, Olga Ciccarelli, Alan J Thompson, 2008, Archives of neurology.

Magnetic resonance imaging in primary progressive multiple sclerosis.

A. Thompson, G. Ingle, David H. Miller, 2002, Journal of rehabilitation research and development.

Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study

Peter Kapeller, G. Barker, M. McLean, 2001, Journal of Neurology.

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

Ludwig Kappos, Massimo Filippi, Alan J. Thompson, 1997, Journal of Neurology.

Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis

David H. Miller, O. Ciccarelli, A. Thompson, 2017, Multiple Sclerosis.

The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study

David H. Miller, F Barkhof, M Filippi, 2000, Multiple sclerosis.

Optic nerve diffusion tensor imaging in optic neuritis

Gareth J. Barker, S. Anand Trip, Stephen J. Jones, 2006, NeuroImage.

Reduced GABA concentration is associated with physical disability in progressive Multiple Sclerosis

David H. Miller, O. Ciccarelli, R. Edden, 2016 .

Low Myo‐inositol indicating astrocytic damage in a case series of neuromyelitis optica

David H. Miller, O. Ciccarelli, A. Thompson, 2013, Annals of neurology.

ADC mapping of the human optic nerve: Increased resolution, coverage, and reliability with CSF‐suppressed ZOOM‐EPI

David H. Miller, M. Symms, G. Barker, 2002, Magnetic resonance in medicine.

Lesion volume measurement in multiple sclerosis: How important is accurate repositioning?

D. Miller, P. Tofts, S. Webb, 1996, Journal of magnetic resonance imaging : JMRI.

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

David H. Miller, Jacqueline Palace, G. Giovannoni, 2013, PloS one.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

David H. Miller, D. Arnold, C. Pozzilli, 2016, Multiple sclerosis.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

M. Hutchinson, E. Havrdová, K. Dawson, 2013, Journal of Neurology.

Contiguous‐slice zonally oblique multislice (CO‐ZOOM) diffusion tensor imaging: Examples of in vivo spinal cord and optic nerve applications

David H. Miller, O. Ciccarelli, C. Wheeler-Kingshott, 2009, Journal of magnetic resonance imaging : JMRI.

Chapter 9 Magnetic Resonance Imaging Monitoring in Clinical Trials

David H. Miller, David H. Miller, 2003 .

HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

David H. Miller, J. Hardy, C. Wheeler-Kingshott, 2016, Multiple sclerosis and related disorders.

Magnetic resonance spectroscopy: a possible in vivo marker of disease progression for multiple sclerosis?

David H. Miller, David H. Miller, 2014, JAMA neurology.

Spatial variability and changes of metabolite concentrations in the cortico‐spinal tract in multiple sclerosis using coronal CSI

O. Ciccarelli, A. Thompson, C. Wheeler-Kingshott, 2012, Human brain mapping.

Reproducibility of in vivo metabolite quantification with proton magnetic resonance spectroscopic imaging

David H. Miller, G. Parker, D. MacManus, 2002, Journal of magnetic resonance imaging : JMRI.

The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis

David H. Miller, A. Thompson, G. Barker, 2002, Journal of Neurology.

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a

A. Thompson, D. Altmann, G. Giovannoni, 2001, Journal of Negative Results in BioMedicine.

Role of MRI in diagnosing multiple sclerosis: Magnetic resonance imaging is valuable

David H. Miller, David H. Miller, 2006, BMJ : British Medical Journal.

Feasibility of grey matter and white matter segmentation of the upper cervical cord in vivo: A pilot study with application to magnetisation transfer measurements

David H. Miller, Marios C. Yiannakas, Hugh Kearney, 2012, NeuroImage.

Phenytoin for neuroprotection – Authors' reply

D. Altmann, S. Hickman, R. Kapoor, 2016, The Lancet Neurology.

Author Response: Phenytoin for neuroprotection in acute optic neuritis: a randomised, placebo-controlled, phase 2 trial

D. Altmann, S. Hickman, R. Kapoor, 2016 .

Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter

David H. Miller, Sebastian Brandner, Klaus Schmierer, 2010, Journal of magnetic resonance imaging : JMRI.

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

F. Barkhof, L. Kappos, C. Polman, 2009, BMC neurology.

Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

Marco Rovaris, Massimo Filippi, Xavier Montalban, 2008, Multiple sclerosis.

Natalizumab for Relapsing MS

G. Rice, O. Khan, W. Sheremata, 2003 .

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Anthony O'Hagan, Nicola J Cooper, David H. Miller, 2003, BMJ : British Medical Journal.

Imaging of Demyelination and Remyelination in Multiple Sclerosis

David H. Miller, G. B. Pike, D. Arnold, 2013 .

Demyelinating Diseases of the Optic Nerve

David H. Miller, S. Hickman, David H. Miller, 2005 .

Multiple Sclerosis and Its Treatment

David H. Miller, G. Giovannoni, D. Miller, 1999, Journal of the Royal College of Physicians of London.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2009, Archives of neurology.

Application of a B‐spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three‐dimensional MR images

Olivier Coulon, Alan J Thompson, Simon R Arridge, 2003, Journal of magnetic resonance imaging : JMRI.

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2007, Archives of neurology.

Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy

Paul M. Matthews, Alan J. Thompson, David H. Miller, 2002, Journal of Neurology.

Disability profile of multiple sclerosis in New Zealand

S. Alla, E. Willoughby, J. Pearson, 2016, Journal of Clinical Neuroscience.

Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis.

David H. Miller, O. Ciccarelli, A. Thompson, 2007, Archives of neurology.

Principal component and linear discriminant analysis of T1 histograms of white and grey matter in multiple sclerosis.

David H. Miller, P. Tofts, D. Altmann, 2006, Magnetic resonance imaging.

A quadrant-specific monocular visual functional MRI paradigm designed to minimize attention and loss-of-fixation biases

Laura Mancini, Alan J. Thompson, Gordon T. Plant, 2008 .

Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis☆

David H. Miller, O. Ciccarelli, J. Cohen‐Adad, 2015, NeuroImage: Clinical.

In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan!--Yes.

David H. Miller, 2012, Multiple sclerosis.

Multiple sclerosis—quenching the flames of inflammation

J. Chataway, David H. Miller, 2011, The Lancet.

Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1)

David H. Miller, L. Kappos, C. Polman, 2009 .

Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis

Charlotte Graham, John C Dalrymple-Alford, Tracy R Melzer, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

Treatment of clinically isolated syndrome: to be PreCISe

S. Leary, David H. Miller, 2009, The Lancet.

Cervical transverse myelitis like presentation of cranial dural arteriovenous fistula

David H. Miller, S. Brew, U. Vivekananda, 2013, Clinical Neurology and Neurosurgery.

Use of Two- and Three-Dimensional PET and [ 11 C](R)-PK11195 to Image Focal and Regional Brain Pathology

E. Paulesu, R. Myers, T. Jones, 1998 .

Diffusion tractography based group mapping of major white-matter pathways in the human brain

Gareth J. Barker, Alan J. Thompson, David H. Miller, 2003, NeuroImage.

Changing associations between cognitive impairment and imaging in multiple sclerosis as the disease progresses.

M. Ron, L. Cipolotti, M. Summers, 2013, The Journal of neuropsychiatry and clinical neurosciences.

Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study

Marco Rovaris, Massimo Filippi, Massimiliano Calabrese, 2011, Multiple sclerosis.

A magnetization transfer analysis of the thalamus in schizophrenia.

Gareth J Barker, J. Foong, G. Barker, 2002, The Journal of neuropsychiatry and clinical neurosciences.

An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand

S. Alla, E. Willoughby, J. Pearson, 2016, Multiple sclerosis.

Multiple sclerosis in New Zealand Māori

David H. Miller, S. Alla, J. Pearson, 2014, Multiple sclerosis.

Acute disseminated encephalomyelitis

I. Moseley, W. Mcdonald, B. Kendall, 2016, Neurology.

The role of magnetic resonance techniques in understanding and managing multiple sclerosis.

S. Reingold, D. Miller, R. Grossman, 1998, Brain : a journal of neurology.

Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes

A. Thompson, G. Plant, K. Miszkiel, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis

David H. Miller, David H. Miller, 2004 .

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

A. Thompson, D. Miller, D. MacManus, 1998, Brain : a journal of neurology.

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study.

D. Miller, D. MacManus, B. Kendall, 1993, Brain : a journal of neurology.

Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease

M. Ron, L. Cipolotti, M. Summers, 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.

A. Thompson, D. Miller, D. Altmann, 2008, Brain : a journal of neurology.

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis

M. Battaglini, O. Ciccarelli, A. Thompson, 2010, Journal of Neurology, Neurosurgery & Psychiatry.

MRI only conversion to multiple sclerosis following a clinically isolated syndrome

A. Thompson, G. Plant, K. Miszkiel, 2010, Journal of Neurology, Neurosurgery & Psychiatry.

One year follow up study of primary and transitional progressive multiple sclerosis

A. Thompson, F. Barkhof, M. Rovaris, 2000, Journal of neurology, neurosurgery, and psychiatry.

Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis.

G J Barker, A J Thompson, G T Plant, 2005, Brain : a journal of neurology.

Diffusion MRI in multiple sclerosis

O. Ciccarelli, M. Rovaris, M. Filippi, 2005, Neurology.

Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis

G. Barker, A. Thompson, G. Barker, 1999, Neurology.

Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study.

M. Ron, A. Feinstein, L. Kartsounis, 1992, Journal of neurology, neurosurgery, and psychiatry.

Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.

A. Thompson, G. Plant, D. MacManus, 2004, Brain : a journal of neurology.

Executive function in multiple sclerosis. The role of frontal lobe pathology.

J Foong, A J Thompson, L Rozewicz, 1997, Brain : a journal of neurology.

Reduced Field-of-View Diffusion-Weighted Imaging of the Lumbosacral Enlargement: A Pilot In Vivo Study of the Healthy Spinal Cord at 3T

David H. Miller, S. Ourselin, D. Altmann, 2016, PloS one.

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

A J Thompson, G J M Parker, A. Thompson, 2002, Brain : a journal of neurology.

MRI acquisition and analysis protocol for in vivo intraorbital optic nerve segmentation at 3T.

David H. Miller, Claudia A M Wheeler-Kingshott, C. Wheeler-Kingshott, 2013, Investigative ophthalmology & visual science.

Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis

A J Thompson, D. Miller, D. Tozer, 2009, Journal of magnetic resonance imaging : JMRI.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

F. Barkhof, X. Montalban, L. Kappos, 2014, JAMA neurology.

Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis.

A J Thompson, A. Thompson, G. Plant, 2001, AJNR. American journal of neuroradiology.

Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis

O. Ciccarelli, C. Wheeler-Kingshott, H. Kearney, 2018, Multiple sclerosis.

Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis

Z Khaleeli, A J Thompson, J Sastre-Garriga, 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

Early MRI in optic neuritis

A. Thompson, G. Plant, D. Miller, 2009, Neurology.

Predicting outcome in clinically isolated syndrome using machine learning

O. Ciccarelli, A. Thompson, N. De Stefano, 2014, NeuroImage: Clinical.

Correction for variations in MRI scanner sensitivity in brain studies with histogram matching

David H. Miller, G. Barker, D. Miller, 1998, Magnetic resonance in medicine.

W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century.

E. Frohman, O. Stuve, David H. Miller, 2007, Archives of neurology.

Recent Advances in Neuroimaging of Multiple Sclerosis

David H. Miller, W. Rashid, David H. Miller, 2008, Seminars in neurology.

A pilot MRI study of white and grey matter involvement by multiple sclerosis spinal cord lesions.

O. Ciccarelli, D. Miller, K. Miszkiel, 2013, Multiple sclerosis and related disorders.

Measurement of treatment efficacy and new trial results in multiple sclerosis

J. Noseworthy, David H. Miller, 1997, Current opinion in neurology.

Characteristics of lesional and extra-lesional cortical grey matter in relapsing–remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study

David H. Miller, C. Wheeler-Kingshott, D. Tozer, 2016, Multiple sclerosis.

Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: A voxel-based analysis study

C. Wheeler-Kingshott, N. Muhlert, D. Chard, 2015, Multiple sclerosis.

Magnetic resonance spectroscopy: a possible in vivo marker of disease progression for multiple sclerosis?

David H. Miller, 2014, JAMA neurology.

Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis

J. Sastre-Garriga, G. Giovannoni, G. Davies, 2006, Clinical Neurology and Neurosurgery.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

M. Hutchinson, E. Havrdová, M. Sweetser, 2012, New England Journal of Medicine.

Diagnosis of multiple sclerosis: progress and challenges

F. Fazekas, W. Brownlee, T. Hardy, 2017, The Lancet.

Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116)

D. MacManus, X. Montalban, L. Kappos, 2013, Neurology.